Journals / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 2

Prevalence of Restless Legs Syndrome Among Psychiatric Patients Who are Under Antidepressant or Antipsychotic Monotherapy

Pages
161–168
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

ADs and APs should be considered as a cause for RLS when assesing RLS in psychiatric patients who are under treatment either of these medications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Several groups of medications, such as dopamine blockers, analgesics and antihistaminergics were associated with restless legs syndrome (RLS).
📊
Key Findings & Data:Although case reports showed some significant relations, they have many methodological limitations such as co-medications or medical co-morbidities.
💡
Conclusion & Impact:ADs and APs should be considered as a cause for RLS when assesing RLS in psychiatric patients who are under treatment either of these medications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Several groups of medications, such as dopamine blockers, analgesics and antihistaminergics were associated with restless legs syndrome (RLS). Although case reports showed some significant relations, they have many methodological limitations such as co-medications or medical co-morbidities. The aim of this study was to investigate the prevalence and severity of RLS in patients on antidepressant (AD) or antipsychotic (AP) monotherapy. Methods: One hundred and ninety-seven patients and 150 healthy controls were included in the study. RLS was diagnosed according to the International Restless Legs Syndrome Study Group (IRLSSG) criteria. The severity of RLS was evaluated according to IRLSSG rating scale. Participants diagnosed with RLS went under further neurological and psychiatric investigation for excluding secondary causes. Results: One hundred and twenty patients (60.9%) were on AD therapy, while 77 patients (39.1%) were on AP monotherapy. Thirty-two patients (16.2%) and seven controls (4.7%) were diagnosed with RLS according to IRLSSG criteria. The most frequent cause of RLS was quetiapine (28.5%) in the antipsychotic group and paroxetine (22.2%) in the antidepressant group. There was no statistically significant correlation between drug usage duration and RLS severity. Conclusion: AD or AP induced RLS is a common condition. ADs and APs should be considered as a cause for RLS when assesing RLS in psychiatric patients who are under treatment either of these medications.

🔖

Cite This Article

COLAK, B., SEMİZ, M., SOLMAZ, V., AKSOY, D., INANİR, S., GOKBAKAN, M. A., INANİR, A. (2022). Prevalence of Restless Legs Syndrome Among Psychiatric Patients Who are Under Antidepressant or Antipsychotic Monotherapy. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 2, 161–168. https://ajindex.com/articles/573907

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Park YM, Lee HJ, Kang SG, Choi HS, Choi JE, Cho JH, et al. Prevalence of idiopathic and secondary restless legs syndrome in Korean Women. Gen Hosp Psychiatry 2010
  2. 32(2):164-8. [CrossRef] 2. Ekbom K, Ulfberg J. Restless legs syndrome. J Intern Med 2009
  3. 266(5):419-31. [CrossRef] 3. Kang SG, Park YM, Choi JE, Lim SW, Lee HJ, Lee SH, et al. Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Hum Psychopharmacol 2010
  4. 25(5):397-403. [CrossRef] 4. Kim SW, Shin IS, Kim JM, Park KH, Youn T, Yoon JS. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol 2008
  5. 23(7):615-20. [CrossRef] 5. Duggal HS, Mendhekar DN. Clozapine-associated restless legs syndrome. J Clin Psychopharmacol 2007
  6. 27(1):89-90. [CrossRef] 6. Horiguchi J, Yamashita H, Mizuno S, Kuramoto Y, Kagaya A, Yamawaki S, et al. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol 1999
  7. 14(1):33-6. 7. Kang SG, Lee HJ, Kim L. Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. J Psychopharmacol 2009
  8. 23(5):597-601. [CrossRef] 8. Zhao M, Geng T, Qiao L, Zhang M, Shi J, Huang F, et al. Olanzapine-induced restless legs syndrome. J Clin Neurosci 2014
  9. 21(9):1622-5. [CrossRef] 9. Kumar V, Ambekar N, Singh A, Venkatasubramanian G. Successful treatment of antipsychotic-induced restless legs syndrome with gabapentin. Asian J Psychiatr 2014
  10. [CrossRef] 10. Chou KJ, Chen PY, Huang MC. Restless legs syndrome following the combined use of quetiapine and paroxetine. P r o g N e u r o P s y c h o p h a r m a c o l B i o l P s y c h i a t r y 2010
  11. 34(6):1139-40. [CrossRef] 11. Urbano MR, Ware JC. Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder. J Clin Psychopharmacol 2008
  12. 28(6):704-5. [CrossRef] 12. Wetter TC, Brunner J, Bronisch T. Restless legs syndrome p r o b a b l y i n d u c e d b y r i s p e r i d o n e t r e a t m e n t. Pharmacopsychiatry 2002
  13. 35(3):109-11. [CrossRef] 13. Bolanos-Vergaray J, Obaya JC, Gonzalez R, Echeverri C, Piquer P. Restless legs syndrome due to aripiprazole. Eur J Clin Pharmacol 2011
  14. 67(5):539-40. [CrossRef] 14. Hargrave R, Beckley DJ. Restless legs syndrome exacerbated by sertraline. Psychosomatics 1998
  15. 39(2):177-8. [CrossRef] 15. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci